罗欣药业预计前三季度净利2270万元至2520万元，同比扭亏为盈

Core Viewpoint - 罗欣药业预计2025年前三季度实现归属净利润2270万元至2520万元，较上年同期的-2.65亿元有显著改善 [1] Group 1: Financial Performance - The company forecasts a net profit attributable to shareholders of approximately 22.7 million to 25.2 million yuan for the first three quarters of 2025, compared to a loss of 265 million yuan in the same period last year [1] Group 2: Product Development - The commercialization process of the core innovative drug,替戈拉生片, has deepened, with the commercial team making positive progress in market expansion and access [1] - The product's terminal coverage in target markets has continuously expanded, leading to a significant year-on-year increase in sales, which has become a key driver of performance growth [1] Group 3: Operational Efficiency - During the reporting period, the company has optimized its working capital management by organizing a special collection of receivables, effectively improving operating cash flow and reducing bad debt losses [1]